598 related articles for article (PubMed ID: 16279562)
1. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
White AA; Stevenson DD; Simon RA
Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562
[TBL] [Abstract][Full Text] [Related]
2. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
Berges-Gimeno MP; Simon RA; Stevenson DD
Clin Exp Allergy; 2002 Oct; 32(10):1491-6. PubMed ID: 12372130
[TBL] [Abstract][Full Text] [Related]
3. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.
Stevenson DD; Mehra PK; White AA; Gupta S; Woessner KM; Simon RA
J Allergy Clin Immunol; 2005 Oct; 116(4):755-60. PubMed ID: 16210047
[TBL] [Abstract][Full Text] [Related]
4. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
Berges-Gimeno MP; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2002 Nov; 89(5):474-8. PubMed ID: 12452205
[TBL] [Abstract][Full Text] [Related]
5. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis.
Dursun AB; Woessner KA; Simon RA; Karasoy D; Stevenson DD
Ann Allergy Asthma Immunol; 2008 May; 100(5):420-5. PubMed ID: 18517072
[TBL] [Abstract][Full Text] [Related]
6. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
White A; Ludington E; Mehra P; Stevenson DD; Simon RA
Ann Allergy Asthma Immunol; 2006 Nov; 97(5):688-93. PubMed ID: 17165280
[TBL] [Abstract][Full Text] [Related]
7. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
8. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges.
Williams AN; Simon RA; Woessner KM; Stevenson DD
J Allergy Clin Immunol; 2007 Aug; 120(2):273-7. PubMed ID: 17481713
[TBL] [Abstract][Full Text] [Related]
9. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease.
White A; Bigby T; Stevenson D
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):190-5. PubMed ID: 16937750
[TBL] [Abstract][Full Text] [Related]
10. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
Katial RK; Strand M; Prasertsuntarasai T; Leung R; Zheng W; Alam R
J Allergy Clin Immunol; 2010 Oct; 126(4):738-44. PubMed ID: 20728206
[TBL] [Abstract][Full Text] [Related]
11. Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
Fraj J; Valero A; Vives R; Pérez I; Borja J; Izquierdo I; Picado C
Allergy; 2008 Jan; 63(1):112-5. PubMed ID: 18053020
[TBL] [Abstract][Full Text] [Related]
12. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
Mullol J; Picado C
Immunol Allergy Clin North Am; 2013 May; 33(2):163-76. PubMed ID: 23639706
[TBL] [Abstract][Full Text] [Related]
13. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.
Berges-Gimeno MP; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2003 Mar; 90(3):338-41. PubMed ID: 12669898
[TBL] [Abstract][Full Text] [Related]
14. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.
Mascia K; Haselkorn T; Deniz YM; Miller DP; Bleecker ER; Borish L;
J Allergy Clin Immunol; 2005 Nov; 116(5):970-5. PubMed ID: 16275362
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to nonsteroidal anti-inflammatory drugs.
Namazy JA; Simon RA
Ann Allergy Asthma Immunol; 2002 Dec; 89(6):542-50; quiz 550, 605. PubMed ID: 12487218
[TBL] [Abstract][Full Text] [Related]
16. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.
Lee RU; White AA; Ding D; Dursun AB; Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2010 Aug; 105(2):130-5. PubMed ID: 20674823
[TBL] [Abstract][Full Text] [Related]
17. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease.
Hope AP; Woessner KA; Simon RA; Stevenson DD
J Allergy Clin Immunol; 2009 Feb; 123(2):406-10. PubMed ID: 19056109
[TBL] [Abstract][Full Text] [Related]
18. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
Macy E; Bernstein JA; Castells MC; Gawchik SM; Lee TH; Settipane RA; Simon RA; Wald J; Woessner KM;
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):172-4. PubMed ID: 17304886
[TBL] [Abstract][Full Text] [Related]
19. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
20. Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis.
Schapowal AG; Simon HU; Schmitz-Schumann M
Acta Otorhinolaryngol Belg; 1995; 49(3):235-50. PubMed ID: 7484142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
